LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.50−0.32 (-8.38%)
Close on Nov 17, 2026Market cap $109.97MP/E –Yield –
LENZ Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
LENZ Therapeutics's price to sales ratio was 6.0× on Nov 11, 2026, against 49.9× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 6.0× | −20.1 |
| 2025 | Dec 31, 2025 | 26.1× | – |
See a number that looks wrong?